Adaptimmune to Report Fourth Quarter/ Total 12 months 2020 Monetary Effects and Enterprise Updates on …

Push release articles from World Newswire. The AP information employees was not involved in its creation.

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (World NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to handle most cancers, will report economical outcomes and provide small business updates for the fourth quarter and 12 months ended December 31, 2020, before the US marketplaces open up on Thursday, February 25, 2021. Next the announcement, the Corporation will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that exact day (specifics underneath).

The push release and the live webcast of the meeting get in touch with will be out there in the trader part of Adaptimmune’s company website at  www.adaptimmune.com. An archive will be readily available following the phone at that very same handle.

To participate in the live meeting get in touch with, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). Soon after positioning the phone, you should check with to be joined into the Adaptimmune meeting simply call and deliver the confirmation code (2099860).

About Adaptimmune
Adaptimmune is a clinical-phase biopharmaceutical business concentrated on the improvement of novel cancer immunotherapy items for folks with cancer. The Company’s exceptional SPEAR® (Distinct Peptide Enhanced Affinity Receptor) T-cell system enables the engineering of T-cells to concentrate on and wipe out most cancers throughout several good tumors.

Ahead-Seeking Statements
This release has “forward-searching statements” within the that means of the Non-public Securities Litigation Reform Act of 1995 (PSLRA). These forward-on the lookout statements require specific hazards and uncertainties. These types of hazards and uncertainties could cause our actual results to differ materially from these indicated by these types of ahead-seeking statements, and incorporate, without limitation: the achievement, expense and timing of our solution progress pursuits and medical trials and our means to effectively progress our TCR therapeutic candidates through the regulatory and commercialization processes. For a more description of the hazards and uncertainties that could lead to our true success to vary materially from those expressed in these ahead-looking statements, as properly as pitfalls relating to our organization in normal, we refer you to our Quarterly Report on Form 10-Q submitted with the SEC on November 5, 2020, and our other SEC filings. The forward-seeking statements contained in this push release talk only as of the date the statements have been produced and we do not undertake any obligation to update these types of ahead-looking statements to mirror subsequent gatherings or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
[email protected]

Trader Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
[email protected]